Kyverna Therapeutics Inc (KYTX) Unusual Options Activity Today

Checking KYTX unusual options activity helps you spot when traders are making outsized bets on Kyverna Therapeutics Inc before the broader market catches on. Kyverna Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor KYTX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching KYTX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking KYTX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and KYTX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis.

Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Catalysts rarely arrive without a footprint, and KYTX unusual options activity is often where that footprint shows up first. Our scanner tracks Kyverna Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at KYTX unusual options volume on the call side or chasing put sweeps, Kyverna Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.